Andrew J. Muir

Best Publications

• Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

  Dongliang Ge;Jacques Fellay;Alexander J. Thompson;Jason S. Simon

  4501
  Citations

• Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

  Ira M. Jacobson;John G. McHutchison;Geoffrey Dusheiko;Adrian M. Di Bisceglie

  3244
  Citations

• Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

  Nezam Afdhal;Stefan Zeuzem;Paul Kwo;Mario Chojkier

  2134
  Citations

• Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

  John G. McHutchison;Eric J. Lawitz;Mitchell L. Shiffman;Andrew J. Muir

  1792
  Citations

• Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

  Nezam Afdhal;K. Rajender Reddy;David R. Nelson;Eric Lawitz

  1667
  Citations

• Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

  Kris V. Kowdley;Stuart C. Gordon;K. Rajender Reddy;Lorenzo Rossaro

  1480
  Citations

• Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

  John G. McHutchison;Gregory T. Everson;Stuart C. Gordon;Ira M. Jacobson

  1408
  Citations

• Telaprevir for previously treated chronic HCV infection.

  John G. McHutchison;Michael P. Manns;Andrew J. Muir;Norah A. Terrault

  956
  Citations

• Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

  Alexander J. Thompson;Andrew J. Muir;Andrew J. Muir;Mark S. Sulkowski;Dongliang Ge

  953
  Citations

• Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis

  M. P. Curry;J. G. O'Leary;N. Bzowej;A. J. Muir

  922
  Citations

• Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

  Michael Charlton;Gregory T. Everson;Steven L. Flamm;Princy Kumar

  921
  Citations

• Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.

  Andrew J. Muir;Jeffrey D. Bornstein;Paul G. Killenberg

  778
  Citations

• ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

  Jacques Fellay;Alexander J. Thompson;Dongliang Ge;Curtis E. Gumbs

  545
  Citations

• Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin

  Jeanette J. McCarthy;Josephine H. Li;Alexander Thompson;Sunil Suchindran

  462
  Citations

• Disparities in Liver Transplantation Before and After Introduction of the MELD Score

  Cynthia A. Moylan;Carla W. Brady;Jeffrey L. Johnson;Alastair D. Smith

  421
  Citations

• Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

  Eric Lawitz;Jay P Lalezari;Tarek Hassanein;Kris V Kowdley

  420
  Citations

• Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation

  Michael Charlton;Edward Gane;Michael P. Manns;Robert S. Brown

  403
  Citations

• Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

  Andrew J. Muir;Mitchell L. Shiffman;Atif Zaman;Boris Yoffe

  344
  Citations

• Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

  Stephen A. Harrison;Manal F. Abdelmalek;Stephen Caldwell;Mitchell L. Shiffman

  338
  Citations

• Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

  Paul Y. Kwo;Fred Poordad;Armen Asatryan;Stanley Wang

  323
  Citations